NovoCure Limited (NVCR) revealed the results this week of a clinical trial that put its unique electronic cancer therapy to the test. As a result of this, quotes increased by almost 50% on Tuesday; by Wednesday, the share was valued at $186.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVCR closed at $186.00 at the close of the last trading day, falling by -5.74%. The volume of shares traded increased to 3.22 million, which is higher than the average volume during the last three months of 1.01 million. The stock oscillated between $181.44 and $192.48 during the trading session. There was an earnings-per-share ratio of 0.07. NVCR’s shares have gained 41.23% over the past five sessions and moved 31.85% in the past month; however, it has gained 7.49% annually. Moreover, the stock is currently trading at an RSI of 70.23 with an upward moving average of $152.41 and a downward moving average of $124.76.
NovoCure Limited (NVCR) has created a device called TTFields that disrupts cancer cells’ division by making an electric field. In this device’s case, we can use it as auxiliary therapy without invasive procedures: it’s enough to place electrodes over the tumour, and then automatically, the activity commences.
Research has demonstrated that TTFields is safe: healthy cells located near tumours were untouched during therapy. Hundreds of new trial volunteers will be recruited by NovoCure, and the testing process will be dramatically accelerated. A member of the Independent Data Monitoring Committee (DMC) suggested reducing the duration of a clinical trial’s lead time.
Current NovoCure Limited (NVCR) trials include combinations with chemotherapy and immune checkpoint inhibitors for lung cancer treatment. More than 190 thousand non-small cell lung cancer patients are diagnosed in the United States alone every year, so the market is enormous. NovoCure’s technology could have excellent commercial potential if its therapy proves effective.
